CAJ | 학술논문

背景:检测实验性心肌缺血大鼠的血管活性物质,探讨胸痹通胶囊的药理作用途径.目的:为观察胸痹通胶囊对大鼠心肌缺血时血浆中血管活性物质释放的影响.设计:完全随机分组设计,对照实验.单位:潍坊医学院保健科,生理学教研室,免疫与病原生物学教研室和潍坊市中医院内科.材料:实验于2003-01/2003-06在潍坊医学院生理学教研室完成.选用清洁级Wistar大鼠30只,鼠龄6～8个月,雌雄不限,将动物随机分为正常对照组、模型对照组和模型治疗组.方法:[1]造模前12 h,模型治疗组大鼠灌服胸痹通胶囊(组方:云苓、清夏、枳实、橘红、石菖蒲、灸复花、降香、栝蒌、郁金、丹参、太子参、麦冬、远志、炒枣仁等,经加工制成每粒含生药1g的胶囊)1次,剂量2.5 g/kg,溶于4mL生理盐水中灌胃;造模后10 h再重复灌胃1次.正常对照组和模型对照组在相同时间灌服等量的生理盐水.首次给药后1 h,模型对照组和模型治疗组均按10 mg/kg的剂量皮下注射硫酸异丙基肾上腺素,制成大鼠心肌缺血动物模型.[2]按北京东亚免疫技术研究所提供试剂盒说明书测定血浆内皮素、降钙素基因相关肽、6-酮-前列腺素F1α和血栓素B2.[3]采用方差分析及q检验进行组间对照比较.主要观察指标:各实验组大鼠血浆中血管活性物质的浓度.结果:大鼠30只均进入结果分析.[1]血浆血栓素B2,内皮素水平及血栓素B2/6-酮-前列腺素F1α,内皮素/降钙素基因相关肽:正常对照组和模型治疗组明显低于模型对照组(q=2.99～9.87,P＜0.05～0.01).[2]6-酮-前列腺素F1α,降钙素基因相关肽水平:正常对照组和模型治疗组明显高于模型对照组[(603.3±90.6),(190.0±64.2)ng/L;(560.7±111.1),(174.9±41.4)ng/L;(380 4±705),(114.9±36.4)ng/L,q=3.88～7.64,P＜0.05～0.01].结论:胸痹痛胶囊可明显抑制心肌缺血时缩血管物质的异常释放,并增加扩血管物质的含量,纠正体内重要的血管活性物质血栓素B2、6-酮-前列腺素F1α、内皮素和降钙素基因相关肽含量的失衡. 揹景:檢測實驗性心肌缺血大鼠的血管活性物質,探討胸痺通膠囊的藥理作用途徑.目的:為觀察胸痺通膠囊對大鼠心肌缺血時血漿中血管活性物質釋放的影響.設計:完全隨機分組設計,對照實驗.單位:濰坊醫學院保健科,生理學教研室,免疫與病原生物學教研室和濰坊市中醫院內科.材料:實驗于2003-01/2003-06在濰坊醫學院生理學教研室完成.選用清潔級Wistar大鼠30隻,鼠齡6～8箇月,雌雄不限,將動物隨機分為正常對照組、模型對照組和模型治療組.方法:[1]造模前12 h,模型治療組大鼠灌服胸痺通膠囊(組方:雲苓、清夏、枳實、橘紅、石菖蒲、灸複花、降香、栝蔞、鬱金、丹參、太子參、麥鼕、遠誌、炒棘仁等,經加工製成每粒含生藥1g的膠囊)1次,劑量2.5 g/kg,溶于4mL生理鹽水中灌胃;造模後10 h再重複灌胃1次.正常對照組和模型對照組在相同時間灌服等量的生理鹽水.首次給藥後1 h,模型對照組和模型治療組均按10 mg/kg的劑量皮下註射硫痠異丙基腎上腺素,製成大鼠心肌缺血動物模型.[2]按北京東亞免疫技術研究所提供試劑盒說明書測定血漿內皮素、降鈣素基因相關肽、6-酮-前列腺素F1α和血栓素B2.[3]採用方差分析及q檢驗進行組間對照比較.主要觀察指標:各實驗組大鼠血漿中血管活性物質的濃度.結果:大鼠30隻均進入結果分析.[1]血漿血栓素B2,內皮素水平及血栓素B2/6-酮-前列腺素F1α,內皮素/降鈣素基因相關肽:正常對照組和模型治療組明顯低于模型對照組(q=2.99～9.87,P＜0.05～0.01).[2]6-酮-前列腺素F1α,降鈣素基因相關肽水平:正常對照組和模型治療組明顯高于模型對照組[(603.3±90.6),(190.0±64.2)ng/L;(560.7±111.1),(174.9±41.4)ng/L;(380 4±705),(114.9±36.4)ng/L,q=3.88～7.64,P＜0.05～0.01].結論:胸痺痛膠囊可明顯抑製心肌缺血時縮血管物質的異常釋放,併增加擴血管物質的含量,糾正體內重要的血管活性物質血栓素B2、6-酮-前列腺素F1α、內皮素和降鈣素基因相關肽含量的失衡.
배경:검측실험성심기결혈대서적혈관활성물질,탐토흉비통효낭적약리작용도경.목적:위관찰흉비통효낭대대서심기결혈시혈장중혈관활성물질석방적영향.설계:완전수궤분조설계,대조실험.단위:유방의학원보건과,생이학교연실,면역여병원생물학교연실화유방시중의원내과.재료:실험우2003-01/2003-06재유방의학원생이학교연실완성.선용청길급Wistar대서30지,서령6～8개월,자웅불한,장동물수궤분위정상대조조、모형대조조화모형치료조.방법:[1]조모전12 h,모형치료조대서관복흉비통효낭(조방:운령、청하、지실、귤홍、석창포、구복화、강향、괄루、욱금、단삼、태자삼、맥동、원지、초조인등,경가공제성매립함생약1g적효낭)1차,제량2.5 g/kg,용우4mL생리염수중관위;조모후10 h재중복관위1차.정상대조조화모형대조조재상동시간관복등량적생리염수.수차급약후1 h,모형대조조화모형치료조균안10 mg/kg적제량피하주사류산이병기신상선소,제성대서심기결혈동물모형.[2]안북경동아면역기술연구소제공시제합설명서측정혈장내피소、강개소기인상관태、6-동-전렬선소F1α화혈전소B2.[3]채용방차분석급q검험진행조간대조비교.주요관찰지표:각실험조대서혈장중혈관활성물질적농도.결과:대서30지균진입결과분석.[1]혈장혈전소B2,내피소수평급혈전소B2/6-동-전렬선소F1α,내피소/강개소기인상관태:정상대조조화모형치료조명현저우모형대조조(q=2.99～9.87,P＜0.05～0.01).[2]6-동-전렬선소F1α,강개소기인상관태수평:정상대조조화모형치료조명현고우모형대조조[(603.3±90.6),(190.0±64.2)ng/L;(560.7±111.1),(174.9±41.4)ng/L;(380 4±705),(114.9±36.4)ng/L,q=3.88～7.64,P＜0.05～0.01].결론:흉비통효낭가명현억제심기결혈시축혈관물질적이상석방,병증가확혈관물질적함량,규정체내중요적혈관활성물질혈전소B2、6-동-전렬선소F1α、내피소화강개소기인상관태함량적실형.
BACKGROUND: By detecting vasoactive substances of experimental rats with myocardial ischemia, pharmacological mechanism of xiongbitong was studied in this research.OBJECTIVE: To observe the effect of xiongbitong capsule on release of vasoactive substances of rats with myocardial ischemia.DESIGN: A completely randomized controlled study.SETTING: Department of Health, Weifang Medical College; Department of Physiology, Department of Immunity and Pathogenic Biology, Department of Internal Medicine, Weifang College of Traditional Chinese Medicine.MATERIALS: The experiment had been carried out in the Laboratory of Physiology of Weifang Medical College from January 2003 to June 2003.The cleansing grade 30 Wistar rats, 6-8 months, of either sex, were randomly divided into three groups:namely, normal control group, model control group and model group of treatment with xiongbitong capsule.METHODS: [1] At 12 hours before making model, rats of model treatment group were irrigated with xiongbitong capsule 2.5 g/kg (a capsule contents dried medicinal herbs 1 g), which consists of tuckahoe, rhizoma, immature bitter orange, exocarpium citri grandis, rhizoma acori tatarinowi, moxibustion, dalbergia wood, mongolian snakegourd, curcuma root, red sage root,root of donopsis pilosula, ilyturf root, ophiopogon, polygala root, date kernel etc., and dissolved in 4 mL physiological saline. AT ten hours after making model, they were irrigated with same dose once more. The rats of normal control group and model control group were irrigated with the same dose physiological saline at the same time. One hour after the first irrigation, the animal models of myocardial ischemia of rats of model control group and model treatment group were established by injecting vitriol isoprenaline according to 10 mg/kg subcutaneously. [2] Endothelin (ET), calcitonin generelates peptide (CGRP), 6-keto-prostaglandin Fl alpha (6-keto-PGF1α) and thromboxane B2 (TXB2) in the plasma of rats were detected according to the explanation of Institute of Beijing East Asia Immune Technique. [3] The analysis of variance and q test were used for comparing between groups.MAIN OUTCOME MEASURES: Contents of vasoactive substances in the plasma of rats in each experimental group.RESULTS: The date of all thirty rats was entered the final analysis. [1]The contents of (TXB2) and ET, TXB2/6-Keto-PGF1α, ET/CGRP: Compared with the model group, the normal control group and model treatment group reduced obviously (q=2.99-9.87, P ＜ 0.05-0.01). [2] The contents of 6-Ke-to-PGF1α and CGRP: Compared with the model group, the normal control group and model treatment group increased obviously [(603.3 ±90.6),(190.0±64.2) ng/L; (560.7±111.1), (174.9±41.4) ng/L; (380.4±705),(114.9±36.4) ng/L, q=3.88-7.64, P ＜ 0.05-0.01].CONCLUSION: Xiongbitong capsule may suppress unusual release of vasoactive material at myocardial ischemia area obviously, increase the content of expanding the blood vessel material, and correct out-of-balance of content of important TXB2, 6-keto-PGF1α, XTB and CGRP in the body.